https://scholars.lib.ntu.edu.tw/handle/123456789/519933
標題: | Pharmacological treatment for Alzheimer's disease: Current approaches and future strategies | 作者: | Fan L.-Y. MING-JANG CHIU |
關鍵字: | Amyloid hypothesis; Cholinesterase inhibitor; Combination therapy; Disease modifying therapy; Tau protein | 公開日期: | 2010 | 卷: | 19 | 期: | 4 | 起(迄)頁: | 228-245 | 來源出版物: | Acta Neurologica Taiwanica | 摘要: | More than a decade after the first approval of the use of acetylcholine esterase inhibitor on patients with Alzheimer's disease, we still not have a single treatment or combination therapy that can effectively stop or reverse the relentless progression of such neurodegenerative disease. Recently therapeutics targeting amyloid hypothesis have undergone scrutiny by many clinical trials. These include gamma secretase inhibitor for reducing beta amyloid formation, agents for preventing aggregation of amyloid oligomers, and immunotherapy for enhancing clearance of amyloid and plaque. Therapies targeting hyperphosphorylated tau is another promising mechanism to be tackled with. Other agents enforcing mitochondria functions, enhancing serotonin receptors, modulating advanced glycation end products, and neurotrophic factors, as well as other therapies are also emerging. We review current treatments and therapeutic strategies already undergone different stage of clinical trails in this report. We propose that therapeutics of various combination composed of symptomatic treatments and disease modifying therapies will become standard regimens of AD treatment with much better efficacy than current approaches. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-79551704780&partnerID=40&md5=26095a2cfe002a88acfcabbdfc6e7b76 https://scholars.lib.ntu.edu.tw/handle/123456789/519933 |
ISSN: | 1019-6099 | SDG/關鍵字: | 6 (3 cyclobutyl 2,3,4,5 tetrahydro 1h 3 benzazepin 7 yloxy) n methylnicotinamide; alpha tocopherol; Alzheimer disease vaccine; atorvastatin; bapineuzumab; cerebrolysin; dimebon; docosahexaenoic acid; donepezil; galantamine; Ginkgo biloba extract; homotaurine; immunoglobulin; isosorbide dinitrate; leteprinim; memantine; methylene blue; omega 3 fatty acid; paliroden; pf 04447943; pf 04494700; placebo; raloxifene; rivastigmine; rosiglitazone; rrx 03140; semagacestat; serotonin 4 agonist; solanezumab; st 101; unclassified drug; unindexed drug; abdominal cramp; Alzheimer disease; amnesia; behavior change; cancer risk; cognition; daily life activity; dementia; dentate gyrus; diarrhea; drug approval; drug efficacy; excitotoxicity; food and drug administration; hippocampus; human; insulin metabolism; nausea; nerve cell plasticity; nonhuman; phase 2 clinical trial (topic); phase 3 clinical trial (topic); protein phosphorylation; randomized controlled trial (topic); review; vomiting; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antipsychotic Agents; Drug Therapy, Combination; Humans |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。